Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
p53, c-erbB2, and PCNA status in benign, proliferative, and malignant ovarian surface epithelial neoplasms - A study of 75 cases
Autore:
Anreder, MB; Freeman, SM; Merogi, A; Halabi, S; Marrogi, AJ;
Indirizzi:
Baptist Mercy Med Ctr, Dept Pathol, New Orleans, LA USA Baptist Mercy Med Ctr New Orleans LA USA ept Pathol, New Orleans, LA USA Tulane118iv, Sch Med & Publ Hlth, Dept Pathol & Lab Med, New Orleans, LA 70 Tulane Univ New Orleans LA USA 70118 Pathol & Lab Med, New Orleans, LA 70 Tulane Univ, Sch Med & Publ Hlth, Dept Epidemiol & Biostat, New Orleans, LA Tulane Univ New Orleans LA USA 70118 Epidemiol & Biostat, New Orleans, LA S Harbor Hosp, Dept Med, Baltimore, MD USA S Harbor Hosp Baltimore MD USA Harbor Hosp, Dept Med, Baltimore, MD USA Louisiana State Univ, Sch Med, Dept Surg, New Orleans, LA USA Louisiana State Univ New Orleans LA USA , Dept Surg, New Orleans, LA USA
Titolo Testata:
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
fascicolo: 4, volume: 123, anno: 1999,
pagine: 310 - 316
SICI:
0003-9985(199904)123:4<310:PCAPSI>2.0.ZU;2-1
Fonte:
ISI
Lingua:
ENG
Soggetto:
CELL NUCLEAR ANTIGEN; STAGE-I CARCINOMAS; BORDERLINE TUMORS; GENE-MUTATIONS; ONCOGENIC EXPRESSION; EMBEDDED TISSUE; BREAST-CANCER; OVEREXPRESSION; PROTEIN; ANTIBODY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
60
Recensione:
Indirizzi per estratti:
Indirizzo: Marrogi, AJ NCI,SAuman Carcinogenesis Lab, NIH, Bldg 37,Room 2C25, Bethesda, MD 20892 U NCI Bldg 37,Room 2C25 Bethesda MD USA 20892 thesda, MD 20892 U
Citazione:
M.B. Anreder et al., "p53, c-erbB2, and PCNA status in benign, proliferative, and malignant ovarian surface epithelial neoplasms - A study of 75 cases", ARCH PATH L, 123(4), 1999, pp. 310-316

Abstract

Low malignant potential tumors of the ovary are believed to behave in a manner intermediate to their benign and malignant counterparts. However, recent evidence suggests these lesions are in fact benign and better classifiedas proliferative. Based on our previous work and evaluating p53, c-erbB2, and PCNA status in a full spectrum of ovarian surface epithelial tumors, with emphasis on low malignant potential tumors, we tested this hypothesis. Immunohistochemical stains with monoclonal antibodies were used an 75 archival ovarian neoplasms. The results demonstrated anti-p53 reactivity in 30 carcinomas (40%), 2 of which were proliferative, and no reactivity in the benign tumors. Overexpression of c-erbB2 was seen in 31 malignant neoplasms (64.5%), 4 of which were proliferative (22.1%), and none in benign tumors. The PCNA proliferative index showed means of 42.8%, 22.8%, and 14.9% with benign, low malignant potential, and malignant tumors, respectively. Predicting immunoreactivity in carcinomas for anti-PCNA (Student t test), anti-p53, and anti-c-erbB2 (Pearson chi(2) test) versus a lack of immunoreactivity inproliferative tumors indicate P values of .001, <.001, and <.001, respectively. These data show significant differences in the expression of these markers in ovarian tumors and suggest a possible role for these oncogenes as supplemental tools in diagnostic pathology. Further, our findings also support the designation of proliferative as opposed to the current nomenclatureof low malignant potential tumors.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/03/20 alle ore 00:27:19